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Increased EGFR (epidermal growth factor receptor) expression has been reported in many types of human cancer and its levels are
positively associated with advanced cancers. Recently, upregulation of Id-1 (inhibitor of differentiation or DNA binding) protein was
found in over 70% of ovarian cancer samples and correlated with poor survival of ovarian cancer patients. However, the molecular
mechanisms responsible for the role of Id-1 in ovarian cancer are not clear. The aim of this study was to investigate the effect of Id-1
on ovarian cancer proliferation and its association with the EGFR pathway. To achieve this, we transfected an Id-1 expression vector
into three ovarian cancer cell lines and examined cell proliferation rate by flow cytometry and bromodeoxyuridine staining. We found
that ectopic Id-1 expression led to increased cell proliferation demonstrated by increased BrdU incorporation rate and S-phase
fraction. The Id-1-induced cell growth was associated with upregulation of EGFR at both transcriptional and protein levels. In contrast,
inactivation of Id-1 through transfection of an Id-1 antisense vector resulted in downregulation of EGFR. Our results indicate that
increased Id-1 in ovarian cancer cells may promote cancer cell proliferation through upregulation of EGFR. Our findings also implicate
that Id-1 may be a potential target for the development of novel strategies in the treatment of ovarian cancer.
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Ovarian cancer is the second leading cause of death from
gynaecologic malignancy worldwide, with a mortality rate of
114.2 per 100000 women (Parkin et al, 2001). Approximately 75%
of women present with ovarian cancer at advanced stage; therefore,
prognosis for this disease is poor, with a 5-year survival rate of less
than 40% (Jemal et al, 2004).
Although the molecular basis for the development of ovarian
cancer is not clear, upregulation of the epidermal growth factor
receptor (EGFR) is reported to be a frequent event in ovarian
cancer and associated with tumour progression, invasion and poor
survival rate (Kohler et al, 1989; Simpson et al, 1995; Skirnisdottir
et al, 2001; Cloven et al, 2004). For example, expression of EGFR is
significantly higher in malignant ovarian cancer cells compared to
borderline and benign tumours (Simpson et al, 1995). A study on
226 patients with different stages of ovarian cancer found that
EGFR-positive staining was evident in approximately 50% of the
patients, and among them 59.8% had recurrent or died of this
disease (Skirnisdottir et al, 2004). Furthermore, in a separate
study, the survival time of patients (n¼111) with EGFR-positive
tumour was much shorter than patients with EGFR-negative
tumours (Kohler et al, 1989). These results indicate that EGFR may
be a key factor in promoting ovarian cancer growth as well as
progression. Recently, using antisense technology, suppression of
EGFR led to inhibition of cellular proliferation, cell adhesion and
tumorigenicity in ovarian cancer cells (Alper et al, 2000). In
addition, targeting the EGFR using an active EGFR-specific
tyrosine kinase inhibitor ZD1839 also resulted in the reduction
of ovarian cancer cell growth (Sewell et al, 2002). These results
further suggest that inactivation of EGFR pathway may provide a
therapeutic target for the treatment of ovarian cancer. However,
the molecular basis of the EGFR-induced ovarian cancer cell
proliferation is still not clear.
Recently, Id-1 (inhibitor of differentiation or DNA binding) has
been suggested as one of the upstream regulators of the EGFR
pathway (Ling et al, 2004). Id-1 is a member of the helix–loop–
helix (HLH) transcription factor family. It lacks the basic domain
for DNA binding and acts as a dominant inhibitor of the basic
HLH transcription factors by forming heterodimers (Benezra et al,
1990). Like EGFR, upregulation of Id-1 is frequently found in many
types of human cancer such as breast (Lin et al, 2000), pancreas
(Maruyama et al, 1999), cervical (Schindl et al, 2001), head and
neck (Langlands et al, 2000) and prostate cancer (Ouyang et al,
2002a), and increased Id-1 expression levels are associated with
advanced tumour stage and poor prognosis (Maruyama et al, 1999;
Schindl et al, 2001; Ouyang et al, 2002a). Recently, it is reported
that over 70% of ovarian cancer samples (among a total of 101
cases) are found to express Id-1 protein, while none of the
nonmalignant cystadenomas shows positive Id-1 staining exam-
ined by immunohistochemistry as well as Western blotting
(Schindl et al, 2003). In addition, the cancer samples with poor
or moderate histological differentiation show stronger Id-1
expression than the well-differentiated tumours. Furthermore,
the overall survival is much shorter in the patients with higher Id-1
expression than the patient with relatively lower Id-1 expression
(Schindl et al, 2003). These results indicate that Id-1 may play an
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yimportant part not only in tumorigenesis but also progression of
ovarian cancer.
The fact that both Id-1 and EGFR protein expression levels
increase with progression and poor prognosis as well as
chemoresistance of ovarian cancer (Alper et al, 2001; Maihle
et al, 2002; Schindl et al, 2003; Cloven et al, 2004) raises a
hypothesis that these two proteins may either share similar
functions or regulate through same pathways. In addition,
evidence from our previous studies has shown that Id-1 promotes
prostate cancer cell proliferation through activation of EGFR (Ling
et al, 2004), indicating that Id-1 may be an upstream regulator of
EGFR. To study the role of Id-1 on ovarian cancer cell growth and
its association with EGFR pathway, in this study, we first
transfected an Id-1 expression vector into three ovarian cancer
cell lines and then examined the effect of ectopic Id-1 expression
on ovarian cancer cell proliferation using bromodeoxyuridine
(BrdU) staining and flow cytometric analysis. The effect of Id-1 on
EGFR expression at both transcriptional and protein levels was
also determined by luciferase assay and Western blotting. These
results were further verified through transfection of an antisense
Id-1 vector in two ovarian cancer cell lines with high levels of Id-1.
Our results suggest that ectopic Id-1 expression stimulates ovarian
cancer cell proliferation and this process is mediated through
upregulation of EGFR. Our results provide novel evidence to
suggest Id-1 as an upstream regulator of the EGFR pathway in
promoting ovarian cancer cell growth.
MATERIALS AND METHODS
Cell lines and cell culture conditions
Five ovarian cancer cell lines, Skov3 (obtained from ATCC,
Manassas, VA, USA), Ovca420, Ovca432, Ovca433, Ovca429, were
maintained in RPMI 1640 (Life Technologies Inc., Carlsbad, CA,
USA) supplemented with 2mML -glutamine and 5% (vv
 1) foetal
calf serum (FCS) at 371C. Ovca420, Ovca432, Ovca433 and Ovca429
were established from freshly isolated ascites or tumour explants
from patients with late-stage ovarian adenocarcinomas with
distinct characteristics (Rauh-Adelmann et al, 2000).
Generation of stable Id-1-expressing transfectants
The pBabe–Id-1 retroviral expression vector and its correspond-
ing vector control were used for generation of stable transfectants.
Details on the vectors as well as transfection procedures have been
described previously (Ouyang et al, 2002b). All the transfectants
were selected and maintained in puromycin (1–2mgml
 1). The
pool of more than 20 individual clones transfected with either Id-1
or pBabe was generated. Cell culture medium was changed to
serum-free medium (SFM) before performing additional experi-
ments.
BrdU staining
Detailed experimental procedures have been described previously
(Wang et al, 2002a). Briefly, monolayer cells were grown on 4-mm
Chamber slides (ICN, Biomedicals, Aurora, OH, USA) and the
culture medium was changed to SFM for 48h. Then, the cells were
treated with BrdU (10mM) for 1h and then washed once with PBS.
The cells were then fixed in cold methanol for 5min at room
temperature and washed in PBS. The cells were incubated with
mouse monoclonal antibody against BrdU (1:10, Roche Diagnos-
tics, Indianapolis, IN, USA) for 1h at 371C and then with anti-
mouse IgG-FITC for 1h at 371C after washing with PBS. The
percentage of FITC-positive cells was evaluated and at least 500
cells were evaluated in each experiment. The percentage of BrdU-
positive cells in the control vector (pBabe) was considered as 100.
The error bars represent the standard deviation generated from
three independent experiments.
Cell cycle analysis
Cells (5 10
5) were plated in 5% FCS culture medium. After 24h,
the culture medium was replaced by SFM for 48h. The cells were
harvested by trypsinisation and then fixed in ice-cold 70% ethanol.
The cells were then washed with PBS and incubated with
propidium iodide (50mgml
 1) and RNase (1mgml
 1) for 30min.
Flow cytometric analysis was performed on an EPICS profile
analyzer and analysed using the ModFit LT2.0 software (Coulter)
as described previously (Wang et al, 2002a).
Western blotting
Detailed experimental procedures were described previously
(Ouyang et al, 2002b). Briefly, whole-cell lysate was prepared by
resuspending cell pellet in lysis buffer (50mM Tris-HCl (pH 8.0),
150mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% SDS)
including protease inhibitors (1mgml
 1 aprotinin, 1mgml
 1
leupeptin, 1mM PMSF), and protein concentrations were measured
using the protein assay kit (Bio-Rad, Hercules, CA, USA). Protein
suspension from the whole-cell lysate (20mg) was loaded onto a
sodium dodecylsulphate–polyacrylamide gel (SDS–PAGE) for
electrophoresis and then transferred to a PVDF membrane
(Amersham, Piscataway, NJ, USA). The membrane was then
incubated with primary antibody for 1h at room temperature
against Id-1, EGFR, b-actin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). After washing with TBS-T, the membrane was incubated
with secondary antibody against mouse or rabbit IgG and the
signals were visualised using ECL plus Western blotting system
(Amersham, Piscataway, NJ, USA).
Luciferase assay
Cells were plated into a 12-well plate at a density of 1 10
5
cellswell
 1. After 24h, the medium was changed to SFM. pER-1
(luciferase reporter containing the EGFR promoter, kindly
provided by Dr A Johnson, NCI, MD, USA) and pRL-CMV-Luc
(internal control) were cotransfected with either the pcDNA,
pcDNA-Id-1 or pcDNA-Id-1-AS, respectively (Ling et al, 2004),
into the cells using Fugene 6 reagent (Roche Diagnostics,
Indianapolis, IN, USA). Cells were lysed 48h after transfection
and were assayed for luciferase activity using the Dual-luciferase
reporter assay system (Promega, WI, USA). Each data point
represented the mean of three experiments and error bars
indicated the standard deviation.
RESULTS
Generation of stable Id-1 transfectants in ovarian cancer
cells
Under in vitro culture conditions, Id-1 expression is usually
dependent on FCS stimulation and this characteristic is more
evident in cell lines exhibiting less aggressive phenotype. For
example, the androgen- or oestrogen-dependent cell lines (i.e.
LNCaP (prostate cancer) and MCF7 (breast cancer)), which
represent less aggressive tumours, show serum-dependent Id-1
expression. In contrast, the androgen- or oestrogen-independent
cell lines (i.e. PC3 (prostate cancer) and MDA-MB-231 (breast
cancer)), which represent aggressive tumours, express the Id-1
protein constitutively regardless of serum concentrations (Lin et al,
2000; Ouyang et al, 2002b). This phenotype provides a tool for
studying the direct role of Id-1 on human cancer cells through
either ectopic introduction or inactivation of the Id-1 gene. In this
study, we first examined Id-1 protein expression in five ovarian
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0%). As shown in Figure 1A, ovarian cancer cell lines Ovca420,
Ovca432 and Ovca433 showed a serum-dependent Id-1 expression,
while the expression of Id-1 was much less serum dependent in the
Ovca429 and Skov3 cells. The Id-1 expression pattern in these
ovarian cancer cell lines also seemed to correlate with their
malignant phenotype. For example, Ovca429 cell line has been
reported to be much more aggressive demonstrated by its highly
invasive nature and increased expression of metastasis promoting
proteins such as uPA and MMP compared to Ovca432 and
Ovca432 cells (Ellerbroek et al, 1998; Ahmed et al, 2002). We then
transfected an Id-1 expression vector into Ovca420, Ovca432 and
Ovca433 cell lines and generated stable transfectants. As shown in
Figure 1B, after selection in puromycin, the Id-1 stable transfec-
tants showed constitutively high levels of Id-1 protein expression
compared to the vector controls when cultured in serum-free
conditions.
Effect of Id-1 expression on serum-independent cell
proliferation in ovarian cancer cells
To investigate the effect of Id-1 expression on ovarian cancer cell
proliferation, the DNA synthesis rate and the cell cycle S-phase
fraction were determined using BrdU staining and cell cycle
analysis, respectively, in the cells cultured in SFM. As shown in
Figure 2, after culturing in SFM for 48 and 72h, the percentage of
BrdU-positive cells in Id-1 transfectants (solid columns) was
higher than the vector controls (open columns) in all three ovarian
cancer cell lines, especially in Ovca432 (up to 10-fold increase).
The small increase of BrdU incorporation in Ovca433 Id-1
transfectant (approximately 1.7–2-fold) may be due to the
relatively high basal levels of Id-1 in the parental cells, which
may facilitate cell proliferation in SFM conditions. Nevertheless,
these results indicate that ectopic expression of Id-1 in ovarian
cancer cells led to increased DNA synthesis rate. To confirm these
results, we performed flow cytometric analysis and studied the S-
phase fraction. As shown in Figure 3, the Id-1 transfectants from
all three cell lines showed higher percentage of S-phase cells after
culturing in SFM for 48 and 72h, respectively. For example, the
A Ovca420 Ovca432 Ovca433 Ovca429 Skov3
5 2.5  1  0
Id-1
Actin
Serum (%) 5 2.5 1  0 5 2.5 1  0 5 2.5 1  0 5 2.5 1  0
B Ovca420
pBabe Id1
Ovca432
pBabe Id-1
Ovca433
pBabe Id-1
Id-1
Actin
Figure 1 Effect of FCS on Id-1 expression in ovarian cancer cell lines and Id-1 expression in stable transfectants. (A) Western blotting analysis of Id-1
protein expression in five ovarian cancer cell lines, Ovca420, Ovca432, Ovca433, Ovca429 and Skov3, in culture medium containing different serum
concentrations. Note that the expression of Id-1 is dependent on FCS in Ovca420, Ovca432 and Ovca433 cell lines but independent in Ovca429 and Skov3
cell lines. (B) Three cell lines Ovca420, Ovca432 and Ovca433 were transfected with an Id-1 expression vector (pBabe–Id-1) or the empty control (pBabe)
and stable transfectants were generated. Id-1 protein expression was examined by Western blotting after culturing in SFM for 48h. Expression of actin was
examined as an internal loading control. Note that Id-1 protein levels are much higher after ectopic expression of the pBabe–Id-1 vector in Ovca420,
Ovca432 and Ovca433 cell lines. Results represent three experiments.
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Figure 2 Effect of ectopic Id-1 expression on ovarian cancer cell
proliferation. (A) BrdU incorporation rate between the Id-1 transfectants
and the vector controls. Cells were cultured in SFM for 48 and 72h,
respectively, and stained with an antibody against BrdU. At least 500 cells
were counted in each experiment and the percentage of BrdU-positive
cells was calculated and compared with the vector controls at 48h time
point, which was assigned as 1. Results presented as the mean and standard
deviation from three experiments. (B) Representative results of BrdU
staining. Strong nuclear FITC-positive signal was considered as BrdU
positive. The background was enhanced to facilitate the counting of total
cell numbers. Note that the percentage of BrdU-positive cells is higher in
Id-1 transfectants than the pBabe control transfectants.
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the vector control only had 9.72% of S-phase cells after culturing in
SFM for 48h. Taken together, these results suggest that upregula-
tion of Id-1 promotes cell proliferation in ovarian cancer cells.
Effect of ectopic Id-1 expression on EGFR in ovarian cancer
cells
As previously suggested, Id-1 promotes cell proliferation through
EGFR pathway in prostate cancer cells (Ling et al, 2004). Next, we
studied if the Id-1-induced cell proliferation in ovarian cancer cells
was mediated through EGFR pathway. As shown in Figure 4A, the
vector-transfected control Ovca420 and Ovca433 cells showed
detectable basal levels of EGFR protein, while EGFR was absent in
Ovca432 cells. After exogenous Id-1 expression, the EGFR protein
level was increased remarkably in all of the Id-1 transfectants
compared with the vector control, suggesting that ectopic Id-1
expression resulted in upregulation of EGFR protein expression.
To confirm these results, luciferase assay was performed to
examine if ectopic Id-1 expression could lead to EGFR activation at
transcriptional level. After cotransfection of pcDNA-Id-1 or
pcDNA vectors with pER-1 (luciferase reporter containing the
EGFR promoter) and pRL-CMV-Luc (internal control) in the
parental cell lines, we found that the EGFR promoter activity was
increased in all three cell lines transfected with the Id-1 expression
vector (solid columns, 250–350% increase) than the cells
transfected with the pcDNA vector control (open columns)
(Figure 4B). Taken together, these results indicate that upregula-
tion of Id-1 in Ovca420, Ovca432 and Ovca433 cells has led to the
upregulation of EGFR expression at both transcriptional and
protein levels.
Effect of antisense Id-1 on the expression of EGFR in
ovarian cancer cells
To further confirm the association between Id-1 and EGFR
expression, we next studied whether blockage of Id-1 expression
could lead to the downregulation of EGFR. As shown in Figure 1A,
the Skov3 and Ovca429 cell lines had constitutively high levels of
Id-1 expression regardless of serum concentrations; we then
transfected a vector containing the antisense sequence to the Id-1
gene (Ling et al, 2003) into these two cell lines and tested the
expression of EGFR. As shown in Figure 5A, 48h after transfection,
the Id-1 protein level was decreased in both cell lines compared to
the pcDNA vector control (up to 70% decrease), indicating a
successful inhibition of Id-1 expression in these cells. In addition,
the expression of the EGFR protein was also downregulated at
SF 72 h
SF48 h
Ovca420 Ovca432 Ovca433
pBabe Id-1 pBabe Id-1  pBabe Id-1
G0-G1: 71.61%
G2-M: 8.19%
S: 20.20%
G0-G1: 77.21%
G2-M: 5.19%
S: 17.59%
G0-G1: 84.04%
G2-M: 3.82%
S: 12.14%
G0-G1: 83.98%
G2-M: 5.17%
S: 10.85%
G0-G1: 76.45 %
G2-M: 6.83% 
S: 16.72%
G0-G1: 70.68%
G2-M: 10.35% 
S: 18.97%
G0-G1: 64.66%
G2-M: 9.74%
S: 25.60%
G0-G1: 64.20%
G2-M: 9.70%
S: 26.10%
G0-G1: 67.12%
G2-M: 12.02% 
S: 20.86%
G0-G1: 69.97%
G2-M: 4.87%
S: 25.17%
G0-G1: 81.84%
G2-M: 8.44%
S: 9.72%
G0-G1: 81.48%
G2-M: 8.39%
S: 10.14%
Figure 3 Effect of ectopic Id-1 expression on cell cycle S-phase fraction. Flow cytometric analysis was performed on the Id-1 and pBabe transfectants after
culturing in SFM for 48 and 72h, respectively. Note that the percentage of S cells is higher in Id-1 transfectants than in the vector control.
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Figure 4 Effect of ectopic Id-1 expression on EGFR. (A) EGFR protein
expression in the Id-1 transfectants and the vector control cells were
cultured in SFM for 48h and EGFR expression was examined by Western
blotting. (B) EGFR promoter activity in Ovca420, Ovca432 and Ovca433
cells transiently transfected with pcDNAId-1 and the vector control
pcDNA. pER-1 (luciferase reporter containing the EGFR promoter) and
pRL-CMV-Luc (internal control) was cotransfected with pcDNA or
pcDNA-Id-1, respectively. Cells were lysed 48h after transfection and
assayed for luciferase activity using the Dual-luciferase reporter assay
system (Promega, WI, USA). The luciferase activity of the cells transfected
with pER-1 and pcDNA was considered as 100%. Each experiment was
repeated three times and the error bars represent the standard deviation
from three independent experiments. Note that ectopic expression of Id-1
in Ovca420, Ovca432 and Ovca433 cells induces upregulation of EGFR at
both transcriptional and protein levels.
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was decreased by 70% in Skov3 cells and the EGFR protein level
was also reduced by approximately 70% compared to the vector-
transfected cells. These results were further confirmed by
luciferase assay, which showed that the EGFR promoter activity
was inhibited in the cells transfected with the antisense Id-1 vector
(solid columns) compared to the vector control (open columns)
(Figure 5B). These results further support the hypothesis that Id-1
may be an upstream regulator of the EGFR signalling pathway.
DISCUSSION
In this study, we have demonstrated the positive effect of Id-1
expression on cell proliferation in three ovarian cancer cell lines
(Figures 1–3). In addition, the evidence provided in this study that
ectopic expression (or downregulation) of Id-1 led to upregulation
(or downregulation) of EGFR at both transcriptional and protein
levels indicates that Id-1 may be an upstream positive regulator of
the EGFR signalling pathway (Figures 4 and 5). Since upregulation
of EGFR is a common event in ovarian cancer, our evidence
implicates a novel mechanism responsible for EGFR activation in
this cancer. As EGFR is one of the key factors in promoting ovarian
cancer cell growth (Alper et al, 2000, 2001; Pack et al, 2004), our
results also suggest an alternative target to suppress EGFR
signalling pathway through inactivation of Id-1, thus inhibiting
cancer cell growth. Although the Id-1-induced cell proliferation in
normal as well as in cancer cells has been reported in several
previous studies (Lin et al, 2000; Ouyang et al, 2002b; Wang et al,
2002b), this study is the first to demonstrate its positive role on
ovarian cancer cell growth, especially its relation with EGFR
pathway in ovarian cancer cells.
Several mechanisms have been suggested for the role of Id-1 in
cell proliferation. For example, Id-1 inhibits p16
INK4a/RB pathway
leading to the bypass of replicative senescence in primary cells
(Alani et al, 2001; Ohtani et al, 2001) and induces serum-
independent proliferation in human prostate cancer cells (Ouyang
et al, 2002b). Recently, the Id-1-induced cell proliferation has been
linked to the Raf-MEK and NF-kB pathways (Ohtani et al, 2001;
Ling et al, 2002, 2003). Since Id-1 is a regulator of transcription, it
is not surprising that it may regulate gene expression involving
multiple signalling pathways. In this study, we found that ectopic
Id-1 expression led to transcriptional activation of EGFR (Figure 4),
while inactivation of Id-1 resulted in suppression of EGFR
expression (Figure 5). Our results indicate a novel downstream
effector of Id-1 in ovarian cancer cells. It is possible that increased
Id-1 expression in ovarian cancer cells may provide autocrine
signals to stimulate EGFR activity, resulting in promotion of cell
proliferation. Since inactivation of EGFR has shown promising
results in inhibition of ovarian cancer cell growth as well as
suppression of metastatic phenotypes, our results suggest a new
target in inhibition of EGFR signalling. Previously, it was also
reported that Id-1 protected against anticancer drug taxol-induced
cell death in nasopharyngeal carcinoma cells (Cheung et al, 2004)
and suppression of Id-1 resulted in sensitisation to TNFa-induced
apoptosis in prostate cancer cells (Ling et al, 2003). Since the front-
line treatment strategy for advanced ovarian cancers is che-
motherapy, downregulation of Id-1 may provide a novel strategy in
improving the efficiency of chemotherapeutic drugs through
suppression of Id-1-induced protection against apoptosis.
Activation of EGFR as well as upregulation of Id-1 have been
associated with aggressive behaviour and poor clinical outcome in
ovarian cancer patients, respectively (Schindl et al, 2003;
Skirnisdottir et al, 2004). In this study, we also found that the
cell lines (i.e. Ovca432, Ovca433) that showed serum-dependent Id-
1 expression had lower basal levels of EGFR and exhibited less
invasive characteristics as reported in previous studies than the
ones with serum-independent Id-1 expression (i.e. Ovca429)
(Ellerbroek et al, 1998; Ahmed et al, 2002). These results further
suggest a strong link between Id-1 and EGFR in promoting ovarian
cancer progression. Recently, the positive role of Id-1 in metastasis
has been reported through promoting tumour angiogenesis in a
breast cancer animal model (Fong et al, 2003). In ovarian cancer,
similar effects have been reported in the cells expressing high
levels of EGFR. For example, Ovca8 cells expressing high levels of
EGFR were much more invasive and contained high levels of
integrins and MMP activity and these malignant phenotypes were
suppressed when EGFR was inactivated through antisense
technology (Alper et al, 2001). It is possible that increased
expression of Id-1 and EGFR proteins may provide growth
advantage for ovarian cancer cells to progress to more advanced
malignant phenotype leading to poor prognosis in patients.
However, how Id-1 and EGFR interact with each other and what
signalling pathways are responsible for mediating ovarian cancer
proliferation and progression remain to be elucidated.
In summary, we have provided first evidence that Id-1 plays an
important part in the proliferation of ovarian cancer cells and this
function is mediated through upregulation of EGFR. Although
further investigations are needed to elucidate the precise molecular
mechanisms responsible for the role of Id-1 in ovarian cancer, our
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Figure 5 Effect of Id-1 inactivation on EGFR. (A) Id-1 and EGFR protein
expression in ovarian cancer cells transiently transfected with an antisense
Id-1 expression vector (pcDNA-Id-1-AS) and the control vector (pcDNA).
Cells were cultured in SFM for 48h after transfection and Id-1 and EGFR
expression was examined by Western blotting. (B) EGFR promoter activity
in ovarian cancer cells transiently transfected with Id1-AS and the vector
control. pER-1 (luciferase reporter containing the EGFR promoter) and
pRL-CMV-Luc (internal control) were cotransfected with pcDNA or
pcDNA-Id-1-AS, respectively, to Skov3 and Ovca429 cells. Cells were lysed
for luciferase assays 48h after transfection and the luciferase activity was
tested using the Dual-luciferase reporter assay system (Promega, WI, USA).
Samples transfected with pER-1 and pcDNA was considered as 100%. The
error bars represent standard deviation from three independent experi-
ments. Note that inhibition of Id-1 expression in Skov3 and Ovca429 cells
reduces EGFR expression at both transcriptional and protein levels.
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Since inhibition of EGFR is effective in the suppression of ovarian
cancer cell growth, inactivation of Id-1 may provide an alternative
strategy for the treatment of this cancer.
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